BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1230 related articles for article (PubMed ID: 28825375)

  • 21. Direct oral anticoagulants in patients with cancer.
    Bossaer JB; Covert KL
    Am J Health Syst Pharm; 2019 Jul; 76(14):1019-1027. PubMed ID: 31361880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
    van Rein N; Biedermann JS; van der Meer FJM; Cannegieter SC; Wiersma N; Vermaas HW; Reitsma PH; Kruip MJHA; Lijfering WM
    J Thromb Haemost; 2017 Jul; 15(7):1386-1391. PubMed ID: 28440008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticoagulation prescribing patterns in patients with cancer.
    Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
    J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
    Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
    PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Castellucci LA; Cameron C; Le Gal G; Rodger MA; Coyle D; Wells PS; Clifford T; Gandara E; Wells G; Carrier M
    JAMA; 2014 Sep; 312(11):1122-35. PubMed ID: 25226478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis.
    Dong Y; Wang Y; Ma RL; Liu M; Gao JZ; Su WY; Yan L; Sun JJ
    J Thromb Thrombolysis; 2019 Oct; 48(3):400-412. PubMed ID: 31062143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
    Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
    Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
    Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants.
    Kim SA; Yhim HY; Bang SM
    J Korean Med Sci; 2019 Feb; 34(6):e52. PubMed ID: 30787683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials.
    Marcucci M; Etxeandia-Ikobaltzeta I; Yang S; Germini F; Gupta S; Agarwal A; Ventresca M; Tang S; Morgano GP; Wang M; Ahmed MM; Neumann I; Izcovich A; Criniti J; Popoff F; Devereaux PJ; Dahm P; Anderson D; Lavikainen LI; Tikkinen KAO; Guyatt GH; Schünemann HJ; Violette PD
    BMJ; 2022 Mar; 376():e066785. PubMed ID: 35264372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
    Hutten BA; Prins MH; Gent M; Ginsberg J; Tijssen JG; Büller HR
    J Clin Oncol; 2000 Sep; 18(17):3078-83. PubMed ID: 10963635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
    Louzada ML; Majeed H; Wells PS
    Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis.
    Sidahmed S; Abdalla A; Kheiri B; Bala A; Salih M; Bachuwa G; Kafri Z; Kuderer NM; Lyman GH
    Crit Rev Oncol Hematol; 2020 Aug; 152():103005. PubMed ID: 32540780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
    Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
    Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.